← Issue №19/ week of Nov 8, 2026/IBD

Anti-TNF Therapy Is Associated With Browning- and Immune-Related Changes in Creeping Fat in Crohn's Disease.

From GI Signals issue №19: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD prospective cohort · n=33 · Nov 1, 2026 · UEG Journal · IF 5.6

Anti-TNF Therapy Is Associated With Browning- and Immune-Related Changes in Creeping Fat in Crohn's Disease.

Basic scienceCrohn's diseaseanti-TNFbasic sciencebiomarker
Clinical takeawayNo clinical action yet: mechanistic findings in human tissue and ex vivo models suggest anti-TNF therapy induces molecular changes in CrF, but functional significance remains unclear.
What it foundAnti-TNF-treated Crohn's disease patients showed higher UCP1 expression in creeping fat (CrF) at mRNA and protein levels, with increased browning-/thermogenesis- and mitochondrial biogenesis-associated gene expression in CrF-derived mature adipocytes.
ContextThis study identifies CrF as an anti-TNF-responsive immunometabolic compartment in Crohn's disease, refining understanding of its role in inflammation and therapy response.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Monfort-Ferré D … Serena C · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
← Read the whole of issue №19 Every paper GI Signals surfaces gets a page like this one. All issues